Evidence map›Paper›PMID 34553842›Full record

ArticleCancer reports (Hoboken, N.J.)2022

Genetic features of B-cell lymphoblastic lymphoma with TCF3-PBX1.

Ryota Shirai, Tomoo Osumi, Aiko Sato-Otsubo, Kazuhiko Nakabayashi, Takeshi Mori, Masanori Yoshida, Kaoru Yoshida, Mika Kohri, Takashi Ishihara, Shiho Yasue and 11 more

Open access · goldAbstract read
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 10 institutions in 1 country.

Ryota ShiraiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0002-1015-3444
Tomoo OsumiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0001-5536-6788
Aiko Sato-OtsuboDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Kazuhiko NakabayashiDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan.
Takeshi MoriDepartment of Hematology and Oncology, Hyogo Prefectural Kobe children's Hospital, Kobe, Japan.
Masanori YoshidaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Kaoru YoshidaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0003-4567-0676
Mika KohriDepartment of Hematology, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.
Takashi IshiharaDepartment of Pediatrics, Nara Medical University, Kashihara, Japan.ORCID 0000-0003-1061-085X
Shiho YasueDepartment of Pediatrics, Graduate School of Medicine, Gifu University, Gifu, Japan.
Toshihiko ImamuraDepartment of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan.
Mikiya EndoDepartment of Pediatrics, Iwate Medical University, Morioka, Japan.
Satoshi MiyamotoDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.
Kentaro OhkiDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Masashi SanadaClinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Japan.
Nobutaka KiyokawaDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takako YoshiokaDepartment of Pathology, National Center for Child Health and Development, Tokyo, Japan.
Kenichiro HataDepartment of Maternal-Fetal Biology, National Research Institute for Child Health and Development, Tokyo, Japan.
Masatoshi TakagiDepartment of Pediatrics and Developmental Biology, Tokyo Medical and Dental University, Tokyo, Japan.ORCID 0000-0002-7580-9184
Motohiro KatoDepartment of Pediatric Hematology and Oncology Research, National Research Institute for Child Health and Development, Tokyo, Japan.ORCID 0000-0001-5145-1774
National Center For Child Health and Development · JPTokyo Medical and Dental University · JPGifu University · JPIwate Medical University · JPKobe Children's Hospital · JPKyoto Prefectural University of Medicine · JPKyoto University · JPNara Medical University · JPNational Hospital Organization · JPSaitama International Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphoblastic lymphoma (LBL) and acute lymphoblastic leukemia (ALL) are categorized as the same entity under precursor lymphoid neoplasms in the World Health Organization classification. However, compared to B-cell ALL, the molecular genetic makeup of B-cell LBL remains to be understood, mainly due to its rarity. We performed whole exome sequencing (WES) on seven patients with TCF3-PBX1-positive B-cell LBL.

methodsWES was performed using DNA extracted from tumor specimens and paired blood samples at remission for six patients, and tumor-only analysis was performed for one patient whose remission sample was not available. For one patient, a relapsed sample was also analyzed.

resultsKMT2D variants and 6q LOH were found as recurrent alterations. Somatic variants of KMT2D were identified in three of the seven patients. Of note, the two patients with heterozygous nonsense variant of KMT2D were at stage III, without bone marrow infiltration. 6q LOH was also identified in two others, out of the seven patients. The common 6q deleted region of the two patients ranged from 6q12 to 6q16.3. Both patients had bone marrow infiltration. Analysis of recurrent case also revealed that the relapsed clone might be derived from a minor clone of the bone marrow at diagnosis.

conclusionIn this study, through WES for seven patients with TCF3-PBX1-positive B-LBL, we identified KMT2D mutations and 6q LOH as recurrent alterations. In order to elucidate the relationship between these recurrent alterations and disease specificity or outcomes, further studies comparing with TCF3-PBX1-positive B-ALL are required.

Indexed as

Oncogene Proteins, FusionPrecursor Cell Lymphoblastic Leukemia-LymphomaBasic Helix-Loop-Helix ProteinsHumansPre-B-Cell Leukemia Transcription Factor 1Basic Helix-Loop-Helix ProteinsOncogene Proteins, FusionPBX1 protein, humanPre-B-Cell Leukemia Transcription Factor 1TCF3-PBX1 fusion protein, humanTCF3 protein, human6q LOHB-cell lymphoblastic lymphomaKMT2DTCF3-PBX1whole exome sequencing

Identifiers

PMID34553842
PMCPMC9458492
OpenAlexW3200882130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.